套细胞淋巴瘤治疗中的悬而未决的问题。

Open questions in the management of mantle cell lymphoma.

机构信息

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

出版信息

Cancer Treat Rev. 2013 Oct;39(6):602-9. doi: 10.1016/j.ctrv.2012.12.013. Epub 2013 Feb 13.

DOI:10.1016/j.ctrv.2012.12.013

Abstract

Mantle cell lymphoma (MCL) is one of the lymphomas with the worse prognosis (median survival 3-5years) as it has an aggressive evolution and at the same time is incurable. Biologically it is characterized by the t(11;14)(q13;q32) translocation leading to overexpression of cyclin D1. This review focuses on a number of controversial issues in the management of this disease, as how to stage patients with a disease which often has extranodal localizations, how to recognize the small subgroup of cases with an indolent course, which treatment is suggested for the young and fit or for the elderly, the role of CNS prophylaxis, rituximab maintenance and radiotherapy, the indications to allogeneic transplantation and the place of new active anti-lymphoma drugs.

摘要

套细胞淋巴瘤（MCL）是预后最差的淋巴瘤之一（中位生存期 3-5 年），因为它具有侵袭性的演变，同时是不可治愈的。从生物学角度来看，它的特征是 t（11;14）（q13;q32）易位导致 cyclin D1 的过度表达。这篇综述集中讨论了该疾病管理中的一些有争议的问题，例如如何对常伴有结外局部病变的患者进行分期，如何识别具有惰性病程的小亚组病例，对年轻且健康或老年患者建议采用何种治疗方案，中枢神经系统预防、利妥昔单抗维持和放疗的作用，异基因移植的适应证以及新型有效抗淋巴瘤药物的应用。